Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQSV3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,249
Award facts
- Contract value 100% obligated
- $10,249.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,249.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 ml vials. This firm fixed-price delivery order, issued on December 15, 2025, with an ultimate completion date of January 7, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. The delivery will be performed in Park Ridge, Illinois, where the company maintains its headquarters and primary operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for military healthcare facilities worldwide. DMS Pharmaceutical Group's prime vendor contract, valued at $499.999 billion with a completion date of December 31, 2036, authorizes the DLA to issue delivery orders for an extensive range of branded and generic pharmaceuticals, biologics, and medical consumables. EXPAREL, a specialty surgical product used for local anesthetic infiltration, represents one component of the company's comprehensive pharmaceutical portfolio supporting Department of Defense healthcare operations globally. No subcontractors are identified in this award documentation.
Quick answers
Who was awarded contract SPE2DR26FQSV3?
SPE2DR26FQSV3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FQSV3 worth?
The government has obligated $10,249 on SPE2DR26FQSV3.
Is contract SPE2DR26FQSV3 an order under another contract?
Yes. SPE2DR26FQSV3 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQSV3 competed?
The extent of competition for SPE2DR26FQSV3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award